Your Molecule matters

A continuum of small to large scale Custom API capabilities

As a Global CDMO we support at every stage of the product lifecycle.

With 25 years of experience in process development, scale-up and ongoing cGMP manufacturing of small molecule APIs, we support emerging, specialty and large pharmaceutical customers for their drug substance or drug delivery needs.


Highly efficient cGMP manufacturing capabilities

As a fully integrated CDMO, Seqens is uniquely positioned to address the continuum of the API value chain : API, HPAPI, cGMP & non-GMP intermediates, RSM, controlled substances, excipient for drug delivery


A trusted supplier
of proprietary APIs

More than 50 APIs have been successfully launched in the United States, Europe and Japan with consistently superior quality, reliability and customer service, supported by regulatory documentation to meet the most stringent standards from local agencies


A continuum of custom synthesis technologies

8 industrial plants and 3 R&D centers in Europe, North America and Asia.

More than 300 scientists, engineers and experts develop tailor-made solutions for its customers and ensure that products are successfully transferred into production.



API Manufacturing / Articles / General / Research and Development

Faster, Less Costly Cinacalcet Production is Among CDMO Responses to Alleviate Rising Cost of Drugs, Impact of Tariffs

Proprietary intermediates produced in Europe, U.S. rather than imported Across the world, the pressure to cut drug price costs has never been greater.
API Manufacturing

Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations

Working with Contract Development & Manufacturing Organizations (CDMOs) in Asia has become a popular strategy for European and U.S.-based sponsors because of the associated lower costs to manufacture complex Active Pharmaceutical Ingredients (APIs).
API Manufacturing

Are CDMOs the Only Ones Reducing Drug Development Costs?

Recently the publication Life Science Leader interviewed the author of the book, “Drugs,…
API Manufacturing

Getting to the Bottom of Genotoxic Impurities in APIs

By Francis Finot, CEO, GeneEvolution and partner of SEQENS’LAB Addressing genotoxic impurities in the creation of Active Pharmaceutical Ingredients (APIs)…

Seqens CDMO global presence

Use interactive map

6 cGMP/FDA inspected sites in EU & US


Pre-GMP sites for RSMs & Intermediates


M3 capacity


DMFs for commercial APIs


Scientists, experts and engineers


R&D centers in UE and US